Amcasertib – 5 mg

Brand:
Cayman
CAS:
1129403-56-0
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Amcasertib is an inhibitor of cancer stem cells (CSCs).{41289} It inhibits the growth of HT-29 and MDA-MB-231 cancer cells (IC50s = 100-250 nM for both) and exhibits a 2-fold increase in potency for a population of SW480 cells enriched for CSCs. Amcasertib reduces spherogenesis of CD44+-enriched FaDu cells. Oral administration of amcasertib (100 mg/kg) reduces tumor growth in PC3, HepG2, FaDu, and MKN45 mouse xenograft models. Amcasertib also inhibits EGFR, C-MET, HER2, and PDGFRα in vitro without reducing global tyrosine kinase activity.  

 

Available on backorder

SKU: 22980 - 5 mg Category:

Description

An inhibitor of cancer stem cells; inhibits the growth of HT-29 and MDA-MB-231 cancer cells (IC50s = 100-250 nM for both); exhibits a 2-fold increase in potency for a population of SW480 cells enriched for CSCs; reduces spherogenesis of CD44+-enriched FaDu cells; reduces tumor growth in PC3, HepG2, FaDu, and MKN45 mouse xenograft models when administered orally at a dose of 100 mg/kg; inhibits EGFR, C-MET, HER2, and PDGFRα in vitro without reducing global tyrosine kinase activity


Formal name: N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-5-(2-phenyl-4-thiazolyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

Synonyms:  BBI503

Molecular weight: 539.7

CAS: 1129403-56-0

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Cancer|Cancer Stem Cell Research||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling